title: The chemotherapy of onchocerciasis XX: ivermectin in combination with albendazole.
abstract: Ivermectin is a potent microfilaricide that also blocks microfilarial release while albendazole is toxic to all intrauterine stages. We investigated whether their combination would permanently sterilize the adult worms. In the first open phase, all 69 patients received 150 micrograms/kg of ivermectin. In the second double-blind phase one week later, 35 patients were randomized to receive 800 mg of albendazole with a fatty breakfast for three consecutive days while 34 patients received matching placebo tablets. Detailed clinical and laboratory examinations were done before treatment and were repeated at intervals over one year. Nodules were excised at three and six months. There was a rapid reduction in skin microfilariae, maximal at four weeks (99.9%). Counts increased subsequently and were between 11 and 18% of initial values at one year. Nodule histology showed no macrofilaricidal activity of the combination. A high proportion of the stretched intrauterine microfilariae were degenerate in both groups. Anterior chamber microfilarial counts were unchanged until day 18 and then fell successively. Low levels persisted in several patients at one year. Dead corneal microfilariae and corneal punctate opacities increased initially, fell with time and then disappeared in most patients. Systemic and ocular reactions were mild to moderate and biochemical abnormalities were minor. A pronounced posttreatment eosinophilia subsided by day 30. There was no significant difference between the two groups in clinical and laboratory tolerance or in alterations in skin and ocular parasites and no important differences in the effect on the adult worms. The combination of ivermectin with albendazole given one week apart is well tolerated but produces no additional effect against Onchocerca volvulus when compared to ivermectin given alone.
authors.affiliation: Onchocerciasis Chemotherapy Research Centre, Hohoe, Ghana.
authors.forename: K
authors.initials: K
authors.lastname: Awadzi
authors.forename: E T
authors.initials: ET
authors.lastname: Addy
authors.forename: N O
authors.initials: NO
authors.lastname: Opoku
authors.forename: A
authors.initials: A
authors.lastname: Plenge-Bönig
authors.forename: D W
authors.initials: DW
authors.lastname: Büttner
mesh_terms: D000293:Adolescent; D000328:Adult; D015766:Albendazole / Q000627:therapeutic use*; D000818:Animals; D000977:Antiparasitic Agents; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005123:Eye / Q000187:drug effects / Q000469:parasitology; D005500:Follow-Up Studies; D006801:Humans; D007559:Ivermectin / Q000627:therapeutic use*; D008297:Male; D008842:Microfilariae / Q000187:drug effects; D008875:Middle Aged; D017181:Onchocerca volvulus / Q000187:drug effects* / Q000302:isolation & purification; D009855:Onchocerciasis / Q000188:drug therapy* / Q000469:parasitology; D015827:Onchocerciasis, Ocular / Q000188:drug therapy / Q000469:parasitology; D012876:Skin Diseases, Parasitic / Q000469:parasitology
chemical_list: D000977:Antiparasitic Agents; D007559:Ivermectin; D015766:Albendazole